HEADER RECORD*******LIBRARY HEADER RECORD!!!!!!!000000000000000000000000000000 SAS SAS SASLIB 9.4 X64_SR12 18JUN21:06:47:2118JUN21:06:47:21 HEADER RECORD*******MEMBER HEADER RECORD!!!!!!!000000000000000001600000000140 HEADER RECORD*******DSCRPTR HEADER RECORD!!!!!!!000000000000000000000000000000 SAS TA SASDATA 9.4 X64_SR12 18JUN21:06:47:2118JUN21:06:47:21 Trial Arms HEADER RECORD*******NAMESTR HEADER RECORD!!!!!!!000000001000000000000000000000 STUDYID Study Identifier DOMAIN Domain Abbreviation ARMCD Planned Arm Code ARM Description of Planned Arm TAETORD Planned Order of Element within Arm 4ETCD Element Code <(ELEMENT Description of Element D7TABRANCHBranch l TATRANS Transition Rule Ł EPOCH Epoch ¤ HEADER RECORD*******OBS HEADER RECORD!!!!!!!000000000000000000000000000000 mRNA-1273-P201TAA100 mRNA-1273 100 ug ASCREEN Screening Randomized to vaccine mRNA-1273 100 ug SCREENING mRNA-1273-P201TAA100 mRNA-1273 100 ug A V-100 mRNA-1273 100 ug BLINDED TREATMENT mRNA-1273-P201TAA100 mRNA-1273 100 ug A0V-100 mRNA-1273 100 ug BLINDED TREATMENT mRNA-1273-P201TAA100 mRNA-1273 100 ug A@FUPA Part A Follow up PART A FOLLOW-UP mRNA-1273-P201TAA100 mRNA-1273 100 ug ApFUPB Part B Follow up PART B FOLLOW-UP mRNA-1273-P201TAA100B mRNA-1273 100 ug - Booster ASCREEN Screening Randomized to vaccine mRNA-1273 100 ug SCREENING mRNA-1273-P201TAA100B mRNA-1273 100 ug - Booster A V-100 mRNA-1273 100 ug BLINDED TREATMENT mRNA-1273-P201TAA100B mRNA-1273 100 ug - Booster A0V-100 mRNA-1273 100 ug BLINDED TREATMENT mRNA-1273-P201TAA100B mRNA-1273 100 ug - Booster A@FUPA Part A Follow up Participant decision visit and agree to receive OL dose PART A FOLLOW-UP mRNA-1273-P201TAA100B mRNA-1273 100 ug - Booster APOL-V-50 Open-Label mRNA-1273 50 ug OPEN LABEL TREATMENTmRNA-1273-P201TAA100B mRNA-1273 100 ug - Booster ApFUPB Part B Follow up PART B FOLLOW-UP mRNA-1273-P201TAA35120 mRNA-1273.351 20 ug ASCREEN Screening Enrolled to mRNA-1273.351 20 ug SCREENING mRNA-1273-P201TAA35120 mRNA-1273.351 20 ug APV351-20 Open-Label mRNA-1273.351 20 ug OPEN LABEL TREATMENTmRNA-1273-P201TAA35120 mRNA-1273.351 20 ug A€FUPC Part C Follow up PART C FOLLOW-UP mRNA-1273-P201TAA35150 mRNA-1273.351 50 ug ASCREEN Screening Enrolled to mRNA-1273.351 50 ug SCREENING mRNA-1273-P201TAA35150 mRNA-1273.351 50 ug APV351-50 Open-Label mRNA-1273.351 50 ug OPEN LABEL TREATMENTmRNA-1273-P201TAA35150 mRNA-1273.351 50 ug A€FUPC Part C Follow up PART C FOLLOW-UP mRNA-1273-P201TAA50 mRNA-1273 50 ug ASCREEN Screening Randomized to vaccine mRNA-1273 50 ug SCREENING mRNA-1273-P201TAA50 mRNA-1273 50 ug A V-50 mRNA-1273 50 ug BLINDED TREATMENT mRNA-1273-P201TAA50 mRNA-1273 50 ug A0V-50 mRNA-1273 50 ug BLINDED TREATMENT mRNA-1273-P201TAA50 mRNA-1273 50 ug A@FUPA Part A Follow up PART A FOLLOW-UP mRNA-1273-P201TAA50 mRNA-1273 50 ug ApFUPB Part B Follow up PART B FOLLOW-UP mRNA-1273-P201TAA50B mRNA-1273 50 ug - Booster ASCREEN Screening Randomized to vaccine mRNA-1273 50 ug SCREENING mRNA-1273-P201TAA50B mRNA-1273 50 ug - Booster A V-50 mRNA-1273 50 ug BLINDED TREATMENT mRNA-1273-P201TAA50B mRNA-1273 50 ug - Booster A0V-50 mRNA-1273 50 ug BLINDED TREATMENT mRNA-1273-P201TAA50B mRNA-1273 50 ug - Booster A@FUPA Part A Follow up Participant decision visit and agree to receive OL dose PART A FOLLOW-UP mRNA-1273-P201TAA50B mRNA-1273 50 ug - Booster APOL-V-50 Open-Label mRNA-1273 50 ug OPEN LABEL TREATMENTmRNA-1273-P201TAA50B mRNA-1273 50 ug - Booster ApFUPB Part B Follow up PART B FOLLOW-UP mRNA-1273-P201TAAA35150mRNA-1273/mRNA-1273.351 50 ugASCREEN Screening Enrolled to mRNA-1273/mRNA-1273.351 50 ug SCREENING mRNA-1273-P201TAAA35150mRNA-1273/mRNA-1273.351 50 ugAPVV351-50Open-Label mRNA-1273/mRNA-1273.351 50 ug OPEN LABEL TREATMENTmRNA-1273-P201TAAA35150mRNA-1273/mRNA-1273.351 50 ugA€FUPC Part C Follow up PART C FOLLOW-UP mRNA-1273-P201TAPLA Placebo ASCREEN Screening Randomized to placebo SCREENING mRNA-1273-P201TAPLA Placebo A PBO Placebo BLINDED TREATMENT mRNA-1273-P201TAPLA Placebo A0PBO Placebo BLINDED TREATMENT mRNA-1273-P201TAPLA Placebo A@FUPA Part A Follow up PART A FOLLOW-UP mRNA-1273-P201TAPLA Placebo ApFUPB Part B Follow up PART B FOLLOW-UP mRNA-1273-P201TAPLAMRNAPlacebo - mRNA-1273 ASCREEN Screening Randomized to placebo SCREENING mRNA-1273-P201TAPLAMRNAPlacebo - mRNA-1273 A PBO Placebo BLINDED TREATMENT mRNA-1273-P201TAPLAMRNAPlacebo - mRNA-1273 A0PBO Placebo BLINDED TREATMENT mRNA-1273-P201TAPLAMRNAPlacebo - mRNA-1273 A@FUPA Part A Follow up Participant decision visit and agree to receive OL dose PART A FOLLOW-UP mRNA-1273-P201TAPLAMRNAPlacebo - mRNA-1273 APOL-V-100Open-Label mRNA-1273 100 ug OPEN LABEL TREATMENTmRNA-1273-P201TAPLAMRNAPlacebo - mRNA-1273 A`OL-V-100Open-Label mRNA-1273 100 ug OPEN LABEL TREATMENTmRNA-1273-P201TAPLAMRNAPlacebo - mRNA-1273 ApFUPB Part B Follow up PART B FOLLOW-UP